This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Reasons to Add Baxter International Stock to Your Portfolio Now
by Zacks Equity Research
BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now
by Zacks Equity Research
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
ACB Stock Likely to Gain From Genome BC-Funded Aroma Research Project
by Zacks Equity Research
Aurora Cannabis' new collaboration on the Genome BC-Funded Project addresses distinct cannabis aromas.
Why Boston Scientific (BSX) Outpaced the Stock Market Today
by Zacks Equity Research
Boston Scientific (BSX) closed at $84.49 in the latest trading session, marking a +0.42% move from the prior day.
SRDX Stock Down Despite FDA Clearance for Pounce XL System
by Zacks Equity Research
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
Here's Why You Should Add BSX Stock to Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.
Reasons to Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors, owing to its strong product portfolio.
TMO Stock Likely to Gain From New International CorEvitas AD Registry
by Zacks Equity Research
Thermo Fisher launches international CorEvitas clinical registry in adolescent AD.
Global Expansion, Strategic Innovations Aid Boston Scientific Stock
by Zacks Equity Research
We are impressed with BSX's recent acquisitions that have added numerous products with immense potential.
t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
by Zacks Equity Research
By integrating ultra-rapid acting insulin such as Lyumjev, which responds faster than traditional insulin, Tandem Diabetes Care is enhancing the pump's functionality.
Reasons to Retain Medtronic Stock in Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic due to strength in its Neurosurgery portfolio. Yet, mounting expenses pose a threat to the company's margins.
Reasons to Add The Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
TMO Stock Gains From Innovation Amid Macroeconomic Issues
by Zacks Equity Research
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost its existing products and services.
RMD Stock Likely to Gain From Enhanced Digital Sleep Health Solutions
by Zacks Equity Research
ResMed introduces digital and personalized solutions designed to improve sleep health.
3 MedTech Stocks to Buy as Monetary Policy Eases
by Urmimala Biswas
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.
Positive Trial Outcome for PulseSelect PFA Likely to Boost MDT Stock
by Zacks Equity Research
Medtronic presents new clinical data on the PulseSelect PFA System and marks its launch in Japan.
BSX Stock Gains From FARAPULSE PFA's PMDA Approval in Japan
by Zacks Equity Research
Boston Scientific achieves PMDA approval for its FARAPULSE PFA System in Japan. The company expects to launch the system in the country in the upcoming weeks.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
by Zacks Equity Research
XRAY continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Zacks.com featured highlights General Motors, Boston Scientific and Assurant
by Zacks Equity Research
General Motors, Boston Scientific and Assurant have been highlighted in this Screen of The Week article.
HAE vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Is HOLX Stock a Smart Hold for Your Portfolio Right Now?
by Zacks Equity Research
Hologic's strength in Molecular Diagnostics is highly promising. Yet, macroeconomic uncertainties can pose headwinds for its operations.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels
by Zacks Equity Research
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Boston Scientific (BSX) closed at $83.08 in the latest trading session, marking a -0.5% move from the prior day.
The S&P 500 to Hit 6,000 Soon? Buy 3 Momentum Stocks Now
by Tirthankar Chakraborty
S&P 500 stocks such as General Motors, Boston Scientific, and Assurant have been selected as the momentum picks for the day using the Driehaus strategy.
MDT Stock Might Gain From Expanded AiBLE Ecosystem and New Partnership
by Zacks Equity Research
Medtronic expands AiBLE spine surgery ecosystem with new technologies and a partnership with Siemens Healthineers.